logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Agios Pharmaceuticals, Inc.

Calculating rank
USPTO Granted Patents = 99

% Expired Patents = 22.2



Trademarks = 27

Forward Citations = 609

Loading Chart...
Loading Chart...

84 inventors (with patents filed for the assignee):

goldMedal Jeffrey O Saunders (31 out of 68 patents)

silverMedal Francesco Gerald Salituro (30 out of 184 patents)

bronzeMedal Jeremy Mark Travins (29 out of 52 patents)

4.  Janeta Popovici-Muller (27 out of 45 patents)

5.  Shunqi Yan (19 out of 27 patents)

6.  Zhenwei Cai (16 out of 20 patents)

7.  Giovanni Cianchetta (15 out of 21 patents)

8.  Shin-San Michael Su (14 out of 15 patents)

9.  Dawei Cui (13 out of 15 patents)

10.  Rene Marc Lemieux (13 out of 21 patents)

11.  Samuel V Agresta (11 out of 14 patents)

12.  Ding Zhou (10 out of 22 patents)

13.  Zenon D Konteatis (9 out of 15 patents)

14.  Zhihua Sui (9 out of 108 patents)

15.  Robert Zahler (7 out of 74 patents)


Core Competencies:
Pyruvate Kinase
Therapeutic Compounds
Cancer Treatment
Cell Proliferation
Combination Therapy
Cytochrome P450
IDH Mutants
Glutaminase Inhibitors
Piperazine Compounds
Metabolic Processes
Brain Tumors
Pharmaceutical Compositions

99 patents:

1. 12673961 - Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations (2026-07-07),
2. 12667087 - METHODS OF TREATMENT WITH AMINOLEVULINIC ACID SYNTHASE 2 (ALAS2) MODULATORS (2026-06-30),
3. 12612381 - Crystalline forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide (2026-04-28),
4. 12428376 - Therapeutic compounds and compositions (2025-09-30),
5. 12377093 - Pyruvate kinase activators for use in therapy (2025-08-05),
6. 12133853 - Pyruvate kinase activators for use in treating blood disorders (2024-11-05),
7. 11957680 - Pyruvate kinase activators for use in treating blood disorders (2024-04-16),
8. 11919915 - Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations (2024-03-05),
9. 11878049 - Mitapivat therapy and modulators of cytochrome P450 (2024-01-23),
10. 11872225 - Pyruvate kinase modulators and use thereof (2024-01-16),
11. 11866411 - Therapeutic compounds and compositions (2024-01-09),
12. 11793806 - Pyruvate kinase activators for use in therapy (2023-10-24),
13. RE49582 - Therapeutic compounds and compositions (2023-07-17),
14. 11590132 - Pyruvate kinase activators for use in treating blood disorders (2023-02-28),
15. 11464775 - Pyruvate kinase modulators and use thereof (2022-10-11),
Company Overview
Agios Pharmaceuticals, Inc., based in Cambridge, MA, specializes in the development of innovative therapies targeting metabolic pathways to treat cancer and rare genetic diseases. The company focuses on pyruvate kinase activators and other therapeutic compounds that influence cell proliferation and metabolism. Agios is dedicated to advancing treatment options through combination therapies and addressing specific genetic mutations, such as IDH mutants, while also exploring the role of glutaminase inhibitors in cancer treatment.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

Agios Pharmaceuticals, Inc. USPTO Patent Assignee Logo
99 Patents

#29 in Cambridge, MA

#212 in Massachusetts

#3,836 in US

#7,865 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Agios Pharmaceuticals, Inc.

Forward Citations = 609

84 inventors:

goldMedal Jeffrey O Saunders (31 out of 68 patents)

silverMedal Francesco Gerald Salituro (30 out of 184 patents)

bronzeMedal Jeremy Mark Travins (29 out of 52 patents)

4.  Janeta Popovici-Muller (27 out of 45 patents)

5.  Shunqi Yan (19 out of 27 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Agios Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/agios-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…